Lupin’s Nagpur Facility Earns US FDA Approval After Flawless Inspection

Lupin Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its injectable facility in Nagpur. The EIR was issued following a successful inspection conducted from June 10 to June 13, 2024, which concluded with zero observations, underscoring Lupin’s commitment to quality and compliance.  

 

Key Highlights:  

Lupin’s achievement reaffirms its dedication to delivering high-quality healthcare solutions and maintaining its reputation as a global leader in the pharmaceutical industry.  

 

Sources: Lupin Investor Relations, Business Standard, MSN News